by: Alex Brown, Inside INdiana Business
Posted: Mar 1, 2021 / 11:37 AM EST / Updated: Mar 1, 2021 / 11:59 AM EST
INDIANAPOLIS (Inside INdiana Business) – Indianapolis-based Eli Lilly and Co. reports positive results from two Phase 3 clinical trials of a drug intended to help people with type 2 diabetes. According to Lilly, tirzepatide resulted in “significant reductions in A1C and body weight” in adults with the disease during the studies.
According to Mike Mason, president of Lilly Diabetes, treatment in adults with type 2 diabetes continued to have “consistent efficacy and safety results” no matter how long they had the disease.
“Significantly lowering A1C levels and weight is a high priority throughout the journey to treating type 2 diabetes. The results we’ve seen so far from three SURPASS studies strengthen our belief in the ability of Tirzepatid to meet those needs, “Mason said.
According to Lilly, the full data from both studies have not yet been evaluated. However, the company plans to present the data at the American Diabetes Association’s scientific meeting in June and release it in a peer-reviewed publication later this year.
You can learn more about Lilly’s clinical studies by clicking here.
